Actively Recruiting
Evaluating Vision-MR Ablation Catheter 2.0 for Treating Type I Atrial Flutter Using MRI Guidance
Led by Imricor Medical Systems · Updated on 2026-10-19
91
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The VISABL-AFL clinical investigation is a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of radiofrequency RF ablation for type-I atrial flutter. This study specifically examines the use of the Vision-MR Ablation Catheter 2.0 within an interventional cardiac magnetic resonance iCMR environment to treat this heart rhythm disorder. Participants receive RF ablation treatment for type I atrial flutter using the Vision-MR Ablation Catheter 2.0 along with the Advantage-MR EP recorder and stimulator system while under iCMR guidance. The study actively monitors the procedures success and safety during and shortly after treatment, focusing on achieving a bi-directional conduction block and observing serious cardiovascular events. Throughout the trial, participants undergo assessments to confirm the treatments effectiveness immediately after the procedure and at 90 days post-treatment. Researchers measure the primary efficacy endpoint by confirming the conduction block during the procedure and monitor safety by tracking serious cardiovascular adverse events for seven days after. Secondary measures include freedom from atrial flutter recurrence and serious adverse events over three months. The study aims to complete participant follow-up by the end of 2026.
CONDITIONS
Brief Title
Atrial Flutter Ablation in the iCMR
Research Team
K
Kate Lindborg
J
Jennifer Somerville
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here